BIOHARVEST SCIENCES INC

At an investor conference BioHarvest Sciences presented its "Botanical Synthesis" platform, announced an expansion of production and a new facility with 20–25 tonnes capacity, and highlighted roughly $100 million in investments and 15 patents. Revenue in 2025 was about $35 million, VINIA cumulative revenue exceeded $100 million; for 2026 a D2C revenue of $33–35 million and consolidated revenue of $37–40 million is expected. The company cited a supply agreement for a fragrance molecule totaling 20 tonnes (valued at $20–30 million for 2027–28) and says it holds 20% of that molecule as well as 25% of a saffron molecule. BioHarvest emphasizes shifting the business from development revenue toward manufacturing and royalties and is using AI for process optimization and quality control. » Plus sur de.investing.com

BioHarvest Sciences reported Q1 revenue of $8.5m, up 8% year‑over‑year, and maintained full‑year guidance of $42m–$48m. CDMO revenue grew 135% driven by progress in fragrance and saffron Botanical Synthesis programs, including Stage 2 agreements valued at over $2m. Net loss widened to $2.6m and adjusted EBITDA loss was $1.2m; cash totaled $20.2m at quarter end. The VINIA D2C business accounted for 95% of sales with 90,000 active users and new product momentum, while the company plans a new manufacturing site operational in H2 2027 and named Nedira Salzman‑Frenkel VP of CDMO business development. » Plus sur finance.yahoo.com

BioHarvest Sciences reports that its brand VINIA became the largest resveratrol dietary supplement brand in the US in 2025, based on NielsenIQ forecasts and Amazon sales data. VINIA generated over USD 30 million in US sales in 2025 and about USD 85 million in cumulative global sales; the last twelve months through Q3/2025 delivered USD 32.72 million (+46% year‑on‑year). The company shows an EPS of -0.68 USD but a gross margin of 59%; roughly 80% of US sales come from direct‑to‑consumer business via VINIA.com. BHST shares trade near a 52‑week low at USD 4.36, while analyst targets of USD 10–15 indicate significant upside potential. » Plus sur de.investing.com